Protocolo diagnóstico de la elevación de transaminasas en el paciente cardiópata

  1. R. Eiros Bachiller 1
  2. J.J. Gávira Gómez 1
  1. 1 Departamento de Cardiología. Clínica Universidad de Navarra. Pamplona
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2016

Título del ejemplar: Enfermedades del aparato digestivo (X) Enfermedades hepáticas

Serie: 12

Número: 10

Páginas: 579-582

Tipo: Artículo

DOI: 10.1016/J.MED.2016.05.006 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Introduction Hepatic injury as a consequence of cardiac disease is a relatively common, but often a poorly recognized syndrome. It is an entity, which should be systematically sought at all professionals who deal with cardiac patients. Clinical management Once suspected contextualization is required and complete the diagnosis by ruling out other possible causes of liver damage in order to perform a specific and targeted therapy approach to treatment of the underlying disease. Aim We describe below the clinical approach of these syndromes being the most relevant heart failure and ischemic heart disease.

Referencias bibliográficas

  • Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11(2):170-7.
  • Ambrosy AP, Gheorghiade M, Bubenek S, Vinereanu D, Vaduganathan M, Macarie C, et al. The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. Eur Heart J Acute Cardiovasc Care. 2013;2(2): 99-108.
  • Bloth B, de Faire U, Edhag O. Extreme elevation of transaminase levels in acute heart diseasea problem in differential diagnosis? Acta Med Scand. 1976;200(4):281-8
  • Kavoliuniene A, Vaitiekiene A, Cesnaite G. Congestive hepatopathy and hypoxic hepatitis in heart failure: a cardiologist’s point of view. Int J Car-diol. 2013;166:554-8.
  • McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dick-stein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart Fail. 2012;14(8):803-69.
  • Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J. 2013;34:2804-11.
  • Van Deursen VM, Damman K, Hillege HL, van Beek AP, van Vel-dhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail. 2010;16:84-90.
  • Wong F. Cirrhotic cardiomyopathy. Hepatol Int. 2009; 3: 294-304.
  • Yasser MF, Reem Y. Hepato-cardiac disorders. World J Hepatol. 2014;6(1):41-54.
Fuente de los datos: Dialnet